References
- Manojna Konda, MD University of Arkansas. GBD Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20:795–820. doi:10.1016/S1474-4422(21)00252-0.
- Schlemm L. Disability Adjusted Life Years due to Ischaemic Stroke Preventable by Real-Time Stroke Detection-A Cost-Utility Analysis of Hypothetical Stroke Detection Devices. Front Neurol. 2018;9:814. doi: 10.3389/fneur.2018.00814.
- Yatsu FM, Yamaguchi T, Norrving B. International aspects of global stroke burden. Int J Stroke. 2006;1(4):222-3. doi: 10.1111/j.1747-4949.2006.00067.x.
- Bonita R, Mendis S, Truelsen T, Bogousslavsky J, Toole J, Yatsu F. The global stroke initiative. Lancet Neurol. 2004;3(7):391-3. doi: 10.1016/ S1474-4422(04)00800-2.
- Rothlisberger JM, Ovbiagele B. Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness. J Comp Eff Res. 2015;4(4):377-84. doi: 10.2217/cer.15.22.
- Roth GJ, Calverley DC. Aspirin, platelets, and thrombosis: theory and practice. Blood. 1994;83(4):885-98.doi.org/10.1182/blood. V83.4.885.885
- Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of anti-platelet therapy for prevention of death, myocar-dial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86. doi: 10.1136/ bmj.324.7329.71.
- Bennett D, Yan B, Macgregor L, Eccleston D, Davis SM. A pilot study of resistance to aspirin in stroke patients. J Clin Neurosci. 2008;15(11):1204-9. doi: 10.1016/j. jocn.2008.01.006.
- Englyst NA, Horsfield G, Kwan J, Byrne CD. Aspirin resistance is more common in lacunar strokes than embolic strokes and is related to stroke severity. J Cereb Blood Flow Metab. 2008;28(6):1196-203. doi: 10.1038/jcbfm.2008.9.
- Berrouschot J, Schwetlick B, von Twickel G, Fischer C, Uhlemann H, Siegemund T, Siegemund A, Roessler A. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand. 2006;113(1):31-5. doi: 10.1111/j.1600-0404.2005.00419.x.
- Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke. 1994;25(12):2331-6. doi: 10.1161/01.str.25.12.2331.
- Macchi L, Petit E, Brizard A, Gil R, Neau JP. Aspirin resistance in vitro and hypertension in stroke patients. J Thromb Haemost. 2004;2(11):2051-3. doi: 10.1111/j.1538-7836.2004.00953.x.
- Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol. 2003;250(1):63-6. doi: 10.1007/s00415-003-0954-y.
- Patel S, Arya V, Saraf A, Bhargava M, Agrawal CS. Aspirin and Clopidogrel Resistance in Indian Patients with Ischemic Stroke and its Associations with Gene Polymorphisms: A Pilot Study. Ann Indian Acad Neurol. 2019;22(2):147-152. doi: 10.4103/aian.AIAN_4_18.
- Sanderson S, Emery J, Baglin T, Kinmonth AL. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med. 2005;142(5):370-80. doi: 10.7326/0003-4819-142-5-200503010-00012.
- Patrono C. Aspirin resistance: Definition, mechanisms and clinical read-outs. J. Thromb. Haemost. 2003, 1, 1710–1713. doi: 10.1046/j.1538-7836.2003.00284.x.
- Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367, 606–617. DOI: https://doi.org/10.1016/S0140-6736(06)68040-9
- Greer DM. Aspirin and antiplatelet agent resistance: implications for prevention of secondary stroke. CNS Drugs. 2010; 24(12):1027-40. doi: 10.2165/11539160-0000000000-00000.
- Aspirin resistance: is it real? Is it clinically significant? Am J Med. 2007;120(1):1-4. doi: 10.1016/j.amjmed.2006.08.023.
- Yi X, Zhou Q, Lin J, Chi L. Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events. Int J Stroke. 2013;8(7):535-9. doi: 10.1111/j.1747-4949.2012.00929.x.
- Roman-Gonzalez A, Naranjo CA, Cardona-Maya WD, et al. Frequency of Aspirin Resistance in Ischemic Stroke Patients and Healthy Controls from Colombia. Stroke Res Treat. 2021; 21;2021:9924710. doi: 10.1155/2021/9924710.
- Ikeda T, Taniguchi R, Watanabe S, et al. Characterization of the antiplatelet effect of aspirin at enrollment and after 2-year follow-up in a real clinical setting in Japan. Circ J. 2010;74(6):1227-35. doi: 10.1253/circj.cj-09-0927.
- Derle E, Öcal R, Kibaroğlu S, et al. Aspirin resistance in cerebrovascular disease and the role of glycoprotein IIIa polymorphism in Turkish stroke patients. Blood Coagul Fibrinolysis. 2016;27(2):169-75. doi: 10.1097/ MBC.0000000000000404.
- Khan H, Kanny O, Syed MH, Qadura M. Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized Therapy. Int J Mol Sci. 2022;23(19):11317. Doi: 10.3390/ ijms231911317.
- Chen WH, Lee PY, Ng W, et al. Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention. Am J Cardiol. 2005; 96(6):760-3. doi: 10.1016/j.amjcard.2005.04.056.
- Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008 Jan 26;336(7637):195-8. doi: 10.1136/bmj.39430.529549.BE. Epub 2008 Jan 17. PMID: 18202034; PMCID: PMC2213873
- Wiśniewski A, Sikora J, Filipska K, Kozera G. Assessment of the relationship between platelet reactivity, vascular risk factors and gender in cerebral ischaemia patients. Neurol Neurochir Pol. 2019;53(4):258-264. doi: 10.5603/PJNNS. a2019.0028.
- Sadeghi M, Emami A, Ziyaei N, Yaran M, Golabchi A, Sadeghi A. Aspirin resistance and ischemic heart disease on Iranian experience. Adv Biomed Res. 2012;1:33. doi: 10.4103/2277-9175.99345.
- Liu XF, Cao J, Fan L, et al. Prevalence of and risk factors for aspirin resistance in elderly patients with coronary artery disease. J Geriatr Cardiol. 2013;10(1):21-7. doi: 10.3969/j.issn.1671-5411.2013.01.005.
- Kahraman S, Dogan A, Ziyrek M, Usta E, Demiroz O, Ciftci C. The association between aspirin resistance and extent and severity of coronary atherosclerosis. North Clin Istanb. 2018;5(4):323-328. doi: 10.14744/nci.2017.26779.
- Fong J, Cheng-Ching E, Hussain MS, Katzan I, Gupta R. Predictors of biochemical aspirin and clopidogrel resistance in patients with ischemic stroke. J StrokeCerebrovasc Dis. 2011;20(3):227-30.doi:10.1016/j.jstrokecerebrovasdis.2009.12.004.
- Meade TW, Brennan PJ. Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ 2000;321:13–7. doi: 10.1136/bmj.321.7252.13.
- Gum PA, Kottke-Marchant K, Poggio Edet al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88(3):230-235. doi: 10.1016/s0002-9149(01)01631-9.
- Anıl B, Sultan Ç, Vildan Y, Murat Ç, Songül Ş. South. Clin. Ist. Euras2018;29(4):225-229. DOI: 10.14744/scie.2018.40427
- Tasdemir E, Toptas T, Demir C, Esen R, Atmaca M. Aspirin resistance in patients with type II diabetes mellitus. Ups J Med Sci. 2014;119(1):25-31. doi: 10.3109/03009734.2013.861549.
- Vardhan G, Kumar V, Agrawal M, et al. Association between Aspirin Resistance and Blood Lipid Profile in Patients of Ischemic Stroke: A Meta-Analysis. Authorea Preprints; 2023. doi: 10.22541/au.167540249.98774953/v1.
- Di Chiara J, Bliden KP, Tantry US, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes. 2007;56(12):3014-9. doi: 10.2337/db07-0707.
- Fateh-Moghadam S, Plöckinger U, Cabeza N, et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol. 2005;42(2):99-103. doi:10.1007/s00592-005-0186-y.
- Schwartz KA. Aspirin resistance: a clinical review focused on the most common cause, non-compliance. Neurohospitalist. 2011;1(2):94-103. doi: 10.1177/1941875210395776.
- Kasotakis G, Pipinos II, Lynch TG. Current evidence and clinical implications of aspirin resistance. J Vasc Surg. 2009;50(6):1500-10. doi: 10.1016/j.jvs.2009.06.023.
- Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. 1994; Stroke, 25:2331-2336.DOI: 10.1161/01.str.25.12.2331.
- Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res. 2002 Oct 1;108(1):37-42. doi: 10.1016/s0049-3848(02)00405-x. PMID: 12586130.
- K.H Grotemeyer. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. 1991; Thromb Res, 63:587-593. doi: 10.1016/0049-3848(91)90085-b.
- Al-Jabi SW. Global Trends in Aspirin Resistance-Related Research from 1990 to 2015: A Bibliometric Analysis. Basic Clin Pharmacol Toxicol. 2017;121(6):512-519. doi: 10.1111/ bcpt.12840.